buy Cerebrolysin

CEREBROLYSIN ®

Clear

Buy Cerebrolysin at Cosmic Nootropic! Various Dosages Available.  

Original Peptide of the Highest Quality by EVER Pharma. Fast US Domestic Delivery within 2-3 days!

Ampoule Sizes in Store: 1ml, 2ml, 5ml, 10ml, and 20ml.

Cerebrolysin Information


Generic name Cerebrolysin
Form: Solution for intramuscular and intravenous injections in ampoules/vials.
Form description: Transparent solution of amber color
Active ingredient: 215.2 mg of Cerebrolysin concentrate (complex of peptides derived from the pig brain tissue) in aqueous solution
Excipients: Sodium hydroxide and water for injection
СAS Number: 12656-61-0
ATC code: N06ВХ Nootropics
Shelf life: 5 years. Do not use it beyond the expiration date printed on the package.
Storage: Store at temperatures not exceeding 25°C (77°F). Do not freeze. Protect from light.
Manufacturer: EVER Pharma, Austria. www.everpharma.com

What is Cerebrolysin?

Cerebrolysin is a neuropeptide preparation with neuroprotective and neurorestorative effects. It comes in an injection form. Cerebrolysin ampoules have several dosages for the convenience of use. 

Cerebrolysin is based on low molecular weight biologically active neuropeptides (20%) and amino acids (80%) isolated from porcine brain tissue by enzymatic cleavage. Read more about Cerebrolysin composition.

Cerebrolysin is used in the complex treatment of acute and chronic disorders of the central nervous system (CNS). It supports endogenous repair and recovery processes after an injury or degenerative disease. It also helps to protect the brain against pathological events and cascades.

How Does Cerebrolysin Work?

Cerebrolysin mechanism of action resides in its ability to activate endogenous defense mechanisms (ESM), which include 4 main components:

  1. Neurotrophics,
  2. Neuroprotection,
  3. Neuroplasticity,
  4. Neurogenesis.

Cerebrolysin Benefits

Cerebrolysin is mainly used in the complex treatment of the following cerebrovascular disorders:

  • Strokes and stroke complications;
  • Alzheimer’s disease and other types of dementia;
  • Traumatic brain injuries;
  • Spinal cord injuries;
  • ADHD in children;
  • Antidepressant-resistant depressions;
  • Other brain diseases.

 

Here is the original 84-page Monograph about Cerebrolysin by EverNeuro Pharma for your information.

Cerebrolysin Side-Effects

Cerebrolysin has an excellent safety record. Unless taken in large amounts (>10 ml), adverse reactions are rare and may include fatigue, headaches, dizziness, and insomnia.

How was Cerebrolysin Invented?

Cerebrolysin nootropic peptide was created in 1949 by Gerhart Harrer, an Austrian Professor, and approved on 1 August 1954. After many success stories, extensive research, and the discovery of neurotrophic regulation, its popularity has increased significantly.

Cerebrolysin is now registered in more than 50 countries, mostly in Europe and Asia. In Austria, the homeland of Cerebrolysin, it’s listed in the Neurorehabilitation after stroke guidelines. In Russia, it is included in the Anti-dementia plan for 2025 under the Ministry of Healthcare of the Russian Federation.

Where Can I Buy Cerebrolysin Online?

Authentic Cerebrolysin ampoules for injection are available at Cosmic Nootropic. We offer the most popular forms: Cerebrolysin 5ml and Cerebrolysin 10ml ampoules as well as other volumes depending on the purpose of use.

We do not require a prescription from you to obtain Cerebrolysin. Buy it fast and safe online in the USA and with international delivery.

Does Cosmic Nootropic sell original Cerebrolysin? – Yes, we do. –> Verify the authenticity of your Cerebrolysin.

Cerebrolysin Experiences

There is a r/Cerebrolysin Reddit page where you can find anecdotal reviews and answers to many of the FAQs about this brain peptide. You can also read some of the customers’ reviews in the ‘Reviews‘ tab above. 

The personal experience of a well-known nootropic enthusiast and personal health coach Lucas Aoun is available to watch on YouTube.

 


Legal Disclaimer
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease. See more

Cerebrolysin Dosage and Duration

Cerebrolysin has indication-specific dosing. The most common regime is intramuscular injections of 5 ml once daily. The common course of treatment is 4 weeks unless otherwise prescribed by the attending physician.

Studies indicate that Cerebrolysin was also used subcutaneously, though the dosages were 0.5–1.0 ml and the effectiveness was lower.

Please refer to more detailed dosage instructions.

How to Inject Cerebrolysin?

Please use sterile needles, sterilize the administration site, wear sterile plastic gloves, administer as soon as you opened the vial.
Relax your muscle and inject slowly –> A couple of tips on how to make injections.

Contraindications

Cerebrolysin should be used with caution by those who are taking antidepressants and MAO-inhibitors, or have kidney issues.

Cerebrolysin Storage Conditions

Please keep Cerebrolysin at room temperature below 30C (86F). Protect from light.
There is no need to keep Cerebrolysin in a fridge unless it’s extremely hot inside.

Shelf life is 5 years. Do not use it beyond the expiration date printed on the package.
Keep the product out of reach of children.

Cerebrolysin Alternatives

Memoprove, Cortexin, Cellex.

CEREBROLYSIN OFFICIAL INSTRUCTION

  1. Rutheret al (1994) Efficacy of the Peptidergic Nootropic Drug Cerebrolysin in Patients with Senile Dementia of the Alzheimer Type (SDAT) https://www.ncbi.nlm.nih.gov/pubmed/8159781
  2. L. Francis-Turner, V. Valouskova (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study https://www.ncbi.nlm.nih.gov/pubmed/8848264
  3. Schwab et al (1997) Morphofunctional effects of moderate forebrain ischemia combined with short-term hypoxia in rats – protective effects of Cerebrolysin https://www.ncbi.nlm.nih.gov/pubmed/9085071
  4. V. Valouskova and A. Gschanes (1999) Effects of NGF, b-FGF, and Cerebrolysin on Water Maze Performance and on Motor Activity of Rats: Short- and Long-Term Study https://www.ncbi.nlm.nih.gov/pubmed/10082636
  5. Masliah et al (1999) Cerebrolysin Ameliorates Performance Deficits, and Neuronal Damage in Apolipoprotein E-Deficient Mice https://www.ncbi.nlm.nih.gov/pubmed/9972690
  6. Bae et al (2000) A Double-Blind, Placebo-Controlled, Multicenter Study of Cerebrolysin for Alzheimer’s Disease https://www.ncbi.nlm.nih.gov/pubmed/11129744
  7. Ruther et al (2000) Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy https://www.ncbi.nlm.nih.gov/pubmed/11005546
  8. Ruether et al (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/11552768
  9. Hartbauer et al (2001) Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons https://www.ncbi.nlm.nih.gov/pubmed/11475013
  10. Hartbauer et al (2001) Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons https://www.ncbi.nlm.nih.gov/pubmed/11459078
  11. Eder et al (2001) Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: An immunohistochemical study on aged rats https://www.ncbi.nlm.nih.gov/pubmed/12197668
  12. Panisset et al (2002) Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent https://www.ncbi.nlm.nih.gov/pubmed/12111446
  13. Rockenstein et al (2003) The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance https://www.ncbi.nlm.nih.gov/pubmed/14628195
  14. Ladurner et al (2004) Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial https://www.ncbi.nlm.nih.gov/pubmed/15583955
  15. Alvarez et al (2006) A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/16420392
  16. Rockenstein et al (2006) Cerebrolysin Decreases Amyloid-b Production by Regulating Amyloid Protein Precursor Maturation in a Transgenic Model of Alzheimer’s Disease https://www.ncbi.nlm.nih.gov/pubmed/16511867
  17. Wei et al (2007) Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/17318304
  18. Ren et al (2007) Cerebrolysin enhances functional recovery following focal cerebral infarction in rats https://www.ncbi.nlm.nih.gov/pubmed/17473393
  19. Alvarez et al (2008) Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate–severe traumatic brain injury https://www.ncbi.nlm.nih.gov/pubmed/18273537
  20. Muresanu et al (2008) A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration https://www.ncbi.nlm.nih.gov/pubmed/18048059
  21. Alvarez et al (2009) Reduced TNF-a and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent Cerebrolysin https://www.ncbi.nlm.nih.gov/pubmed/19531281
  22. Sharma et al (2010) Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat https://www.ncbi.nlm.nih.gov/pubmed/20633118
  23. Guekht et al (2011) Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial https://www.ncbi.nlm.nih.gov/pubmed/20656516
  24. Alcantara-Gonzalez et al (2012) Combined Administration of Cerebrolysin and Donepezil Induces Plastic Changes in Prefrontal Cortex in Aged Mice https://www.ncbi.nlm.nih.gov/pubmed/22826038
  25. Heiss (2012) Cerebrolysin in Patients With Acute Ischemic Stroke in Asia Results of a Double-Blind, Placebo-Controlled Randomized Trial https://www.ncbi.nlm.nih.gov/pubmed/22282884
  26. Menon et al (2012) Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals https://www.ncbi.nlm.nih.gov/pubmed/22229324
  27. Chen et al (2013) Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study https://www.ncbi.nlm.nih.gov/pubmed/23656173
  28. Amiri-Nikpour et al (2014) Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/25516711
  29. Muresanu et al (2015) Cerebrolysin and Recovery After Stroke (CARS) A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial https://www.ncbi.nlm.nih.gov/pubmed/26564102
  30. Ziganshina et al (2016) Cerebrolysin for acute ischaemic stroke https://www.ncbi.nlm.nih.gov/pubmed/27918088

Related products

Longidaza® (Longidaze) is an enzyme / anti-fibrotic supplement. It has a pathogenetic effect in inflammatory processes in the pelvic organs and in other diseases that may lead to fibrosis, and formation of adhesions and scars. Longidaze consists of two active components: enzyme hyaluronidase with direct anti- fibrotic and cleaving (proteolytic) effects; and high molecular weight carrier with an anti-inflammatory effect. It's used in complex and monotherapy of various pathologies.

SEMAX ®

$9.00$90.00

Semax® is a Russian peptide with nootropic properties. You can buy Semax to improve mental and physical performance. The drug was shown to increase BDNF which is responsible for the growth and differentiation of new neurons and synapses. Two forms of Semax are available! It can be used for improving attention and memory (Semax 0.1%) and for treating strokes (Semax 1%). Fast US domestic shipping.

LICOPID ® (GMDP)

$23.00$99.00

Licopid® (or Lycopid) is an immunomodulator containing a complete synthetic analogue of natural GMDP or glucosaminyl muramyl dipeptide. Once in the body, Lycopid mimics the natural process of detecting fragments of peptidoglycan bacteria. Thus, the effect of the drug is as close as possible to the process of natural immunoregulation.

Afobazole® is an anxiolytic drug with nootropic properties that is available OTC in Russia and CIS countries. It stabilises and upregulates GABA and benzodiazepine receptors, exhibits neuroprotective properties, and diminishes anxiety and tensions in the body. Unlike benzos Afobazole does not have sedative, hypnotic, and muscle relaxant action. Fast US domestic shipping is available.